AMX-818: A Next Generation Conditionally Active, Masked T-Cell Engager for the Treatment of HER2-Expressing Solid Tumors.

Time: 11:00 am
day: Day Two


• Exploring the drug discovery process: target identification and validation, antitumor effect, pathway understanding, biomarkers
• Discussing potential indications
• Forecasting monotherapy and/or combination dominated
• Latest data and future directions